|Study Description:||The goal of the first part of this clinical research study is to look at how |
well 3 different doses of sapacitabine can help to control AML in patients who
are least 70 years of age or MDS in patients who are at least 60 years of age.
The safety and tolerability of sapacitabine will also be studied.
The main goal of the second part of the study is to learn if sapacitabine can
improve blood cell counts and lower the amount of leukemia in bone marrow.
The main goal of the third, fourth, and fifth part of this study is to learn
which of the 3 doses of sapacitabine can help to control the disease for at
least one year in patients who are least 70 years of age or older with AML or
60 years of age or older with MDS. Parts 1, 2, 3, and 4 of this study have